zurück

Inebilizumab (indication: neuromyelitis optica spectrum disorders (NMOSD) anti-aquasporin-4 immunoglobulin G (AQP4-IgG) seropositive patients))

 

Subject:

  • Active Sustance: Inebilizumab
  • Name: Uplizna®
  • Therapeutic area: Neuromyelitis optica spectrum disorders (NMOSD)
  • Pharmaceutical company: Horizon Therapeutics GmbH

 

Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023

 

Comparative therapy:

  • Therapy at the physician's discretion, appropriate therapies include:
    • azathioprine OR
    • eculizumab OR
    • mycophenolate mofetil OR
    • rituximab